PMID: 16515471Mar 7, 2006Paper

Recent advances in the stereocontrolled synthesis of antisense phosphorothioates

Mini Reviews in Medicinal Chemistry
Yixin Lu

Abstract

Antisense technology has advanced substantially in the past few decades and now is a well-established therapeutic approach in medicinal chemistry, and it may prove to be a valuable tool in the treatment of a wide range of diseases. Phosphorothioate oligonucleotides are among the most important and promising antisense agents. However, the key drawback lies in their polydiastereomerism, which manifests itself in the different chemical and biological properties of the diastereomeric species. Methodologies towards the stereocontrolled synthesis of antisense phosphorothioate oligonucleotides have been well investigated in recent years. In this review, the progress in this field is summarized.

Citations

Aug 19, 2007·Microbial Cell Factories·Louise Carøe Vohlander RasmussenKim Kusk Mortensen
Feb 14, 2015·Journal of the American Chemical Society·Sibasish PaulMarvin H Caruthers
Sep 5, 2017·Biomedical Chromatography : BMC·N M El ZaharMichael G Bartlett
Aug 19, 2020·The Journal of Organic Chemistry·Karen R Winters, Jean-Luc Montchamp

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.